NCT03035760View on ClinicalTrials.gov

Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 12, 2017

Primary Completion Date

April 23, 2018

Study Completion Date

April 23, 2019

Conditions
Helminthic Infection
Interventions
DRUG

Oxfendazole

methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic. It is the sulphoxide metabolite of fenbendazole.

Trial Locations (1)

52242-2600

University of Iowa - Vaccine Research and Education Unit, Iowa City

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03035760 - Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter